ACADIA Pharmaceuticals (ACAD), a biopharmaceutical company, recently announced their third quarter financial results on November 6, after the market close. The company announced the attainment of various clinical milestones, over the quarter. The share prices of ACADIA dipped almost 7% before the earnings release due to the rumors, which were proved correct, that the losses of the firm will widen in the third quarter.
ACADIA saw a substantial up-rise in its stock prices since the beginning of 2013. This was attributed to the positive clinical trial results of Pimavanserin, a potential treatment for Parkinson's disease psychosis (PDP). The FDA in April agreed to cancel the phase III-021 confirmatory trial for Pimavanserin, owing to the positive...
Only subscribers can access this article, which is part of the PRO research library covering 3,591 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: